PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build
150
PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build
150
PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 0.2.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions
| Draft as of 2024-09-11 |
{
"resourceType" : "CodeSystem",
"id" : "cs-riskfactor-eu-pcsp",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem cs-riskfactor-eu-pcsp</b></p><a name=\"cs-riskfactor-eu-pcsp\"> </a><a name=\"hccs-riskfactor-eu-pcsp\"> </a><a name=\"cs-riskfactor-eu-pcsp-en-US\"> </a><p>This case-sensitive code system <code>http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">1.1<a name=\"cs-riskfactor-eu-pcsp-1.461\"> </a></td><td>RT to a vol exposing the thyroid gland</td><td>RT to a vol exposing the thyroid gland</td></tr><tr><td style=\"white-space:nowrap\">1.2<a name=\"cs-riskfactor-eu-pcsp-1.462\"> </a></td><td>TBI</td><td>TBI</td></tr><tr><td style=\"white-space:nowrap\">1.3<a name=\"cs-riskfactor-eu-pcsp-1.463\"> </a></td><td>MIBG therapy (I-131 MIBG therapy)</td><td>MIBG therapy (I-131 MIBG therapy)</td></tr><tr><td style=\"white-space:nowrap\">2.1<a name=\"cs-riskfactor-eu-pcsp-2.461\"> </a></td><td>RT >= 10 Gy to a vol exposing the breasts</td><td>RT >= 10 Gy to a vol exposing the breasts</td></tr><tr><td style=\"white-space:nowrap\">2.2<a name=\"cs-riskfactor-eu-pcsp-2.462\"> </a></td><td>OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age</td><td>OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age</td></tr><tr><td style=\"white-space:nowrap\">3.1<a name=\"cs-riskfactor-eu-pcsp-3.461\"> </a></td><td>RT >= 35 Gy to a vol exposing the heart</td><td>RT >= 35 Gy to a vol exposing the heart</td></tr><tr><td style=\"white-space:nowrap\">3.2<a name=\"cs-riskfactor-eu-pcsp-3.462\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">3.3<a name=\"cs-riskfactor-eu-pcsp-3.463\"> </a></td><td>RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2</td><td>RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">4.1<a name=\"cs-riskfactor-eu-pcsp-4.461\"> </a></td><td>Alkylating agents</td><td>Alkylating agents</td></tr><tr><td style=\"white-space:nowrap\">4.2<a name=\"cs-riskfactor-eu-pcsp-4.462\"> </a></td><td>RT to a vol exposing the testes</td><td>RT to a vol exposing the testes</td></tr><tr><td style=\"white-space:nowrap\">4.3<a name=\"cs-riskfactor-eu-pcsp-4.463\"> </a></td><td>Including TBI</td><td>Including TBI</td></tr><tr><td style=\"white-space:nowrap\">5.1<a name=\"cs-riskfactor-eu-pcsp-5.461\"> </a></td><td>RT >=12 Gy to a vol exposing the testicles</td><td>RT >=12 Gy to a vol exposing the testicles</td></tr><tr><td style=\"white-space:nowrap\">6.3<a name=\"cs-riskfactor-eu-pcsp-6.463\"> </a></td><td>Surgery to the spinal cord, sympathetic nerves or pelvis</td><td>Surgery to the spinal cord, sympathetic nerves or pelvis</td></tr><tr><td style=\"white-space:nowrap\">6.4<a name=\"cs-riskfactor-eu-pcsp-6.464\"> </a></td><td>Hypogonadal</td><td>Hypogonadal</td></tr><tr><td style=\"white-space:nowrap\">7.2<a name=\"cs-riskfactor-eu-pcsp-7.462\"> </a></td><td>RT to a vol exposing the ovaries</td><td>RT to a vol exposing the ovaries</td></tr><tr><td style=\"white-space:nowrap\">8.1<a name=\"cs-riskfactor-eu-pcsp-8.461\"> </a></td><td>RT >= 30 Gy to a vol exposing the head or the brain</td><td>RT >= 30 Gy to a vol exposing the head or the brain</td></tr><tr><td style=\"white-space:nowrap\">8.2<a name=\"cs-riskfactor-eu-pcsp-8.462\"> </a></td><td>Cisplatin (with or without carboplatin > 1500 mg/m2)</td><td>Cisplatin (with or without carboplatin > 1500 mg/m2)</td></tr><tr><td style=\"white-space:nowrap\">9.1<a name=\"cs-riskfactor-eu-pcsp-9.461\"> </a></td><td>RT to a vol exposing the pancreas</td><td>RT to a vol exposing the pancreas</td></tr><tr><td style=\"white-space:nowrap\">10.2<a name=\"cs-riskfactor-eu-pcsp-10.462\"> </a></td><td>HSCT</td><td>HSCT</td></tr><tr><td style=\"white-space:nowrap\">11.1<a name=\"cs-riskfactor-eu-pcsp-11.461\"> </a></td><td>RT to a volume exposing the hypothalamus or pituatary gland</td><td>RT to a volume exposing the hypothalamus or pituatary gland</td></tr><tr><td style=\"white-space:nowrap\">11.3<a name=\"cs-riskfactor-eu-pcsp-11.463\"> </a></td><td>Hypothalamic or pituitary tumour</td><td>Hypothalamic or pituitary tumour</td></tr><tr><td style=\"white-space:nowrap\">11.4<a name=\"cs-riskfactor-eu-pcsp-11.464\"> </a></td><td>Neurosurgery of the hypothalamus or pituitary gland</td><td>Neurosurgery of the hypothalamus or pituitary gland</td></tr><tr><td style=\"white-space:nowrap\">12.1<a name=\"cs-riskfactor-eu-pcsp-12.461\"> </a></td><td>RT to a vol exposing the kidneys, heart and associated large vessels</td><td>RT to a vol exposing the kidneys, heart and associated large vessels</td></tr><tr><td style=\"white-space:nowrap\">12.3<a name=\"cs-riskfactor-eu-pcsp-12.463\"> </a></td><td>Nephrectomy</td><td>Nephrectomy</td></tr><tr><td style=\"white-space:nowrap\">12.4<a name=\"cs-riskfactor-eu-pcsp-12.464\"> </a></td><td>Ifosfamide</td><td>Ifosfamide</td></tr><tr><td style=\"white-space:nowrap\">12.5<a name=\"cs-riskfactor-eu-pcsp-12.465\"> </a></td><td>Platinium based chemotherapy</td><td>Platinium based chemotherapy</td></tr><tr><td style=\"white-space:nowrap\">12.6<a name=\"cs-riskfactor-eu-pcsp-12.466\"> </a></td><td>Nitrosureas</td><td>Nitrosureas</td></tr><tr><td style=\"white-space:nowrap\">12.7<a name=\"cs-riskfactor-eu-pcsp-12.467\"> </a></td><td>Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)</td><td>Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)</td></tr><tr><td style=\"white-space:nowrap\">13.1<a name=\"cs-riskfactor-eu-pcsp-13.461\"> </a></td><td>Cranial and/or spinal RT</td><td>Cranial and/or spinal RT</td></tr><tr><td style=\"white-space:nowrap\">13.3<a name=\"cs-riskfactor-eu-pcsp-13.463\"> </a></td><td>Methotrexate</td><td>Methotrexate</td></tr><tr><td style=\"white-space:nowrap\">13.4<a name=\"cs-riskfactor-eu-pcsp-13.464\"> </a></td><td>Gonadal failure</td><td>Gonadal failure</td></tr><tr><td style=\"white-space:nowrap\">13.5<a name=\"cs-riskfactor-eu-pcsp-13.465\"> </a></td><td>Growth hormone deficiency</td><td>Growth hormone deficiency</td></tr><tr><td style=\"white-space:nowrap\">13.6<a name=\"cs-riskfactor-eu-pcsp-13.466\"> </a></td><td>Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment</td><td>Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment</td></tr><tr><td style=\"white-space:nowrap\">13.7<a name=\"cs-riskfactor-eu-pcsp-13.467\"> </a></td><td>HSCT, especially with an history of GVHD</td><td>HSCT, especially with an history of GVHD</td></tr><tr><td style=\"white-space:nowrap\">14.3<a name=\"cs-riskfactor-eu-pcsp-14.463\"> </a></td><td>High dose RT</td><td>High dose RT</td></tr><tr><td style=\"white-space:nowrap\">15.1<a name=\"cs-riskfactor-eu-pcsp-15.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region >= 30 Gy</td><td>Radiotherapy to a vol exposing the HP region >= 30 Gy</td></tr><tr><td style=\"white-space:nowrap\">15.2<a name=\"cs-riskfactor-eu-pcsp-15.462\"> </a></td><td>Surgery near or within the HP region</td><td>Surgery near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">15.3<a name=\"cs-riskfactor-eu-pcsp-15.463\"> </a></td><td>CNS tumours near or within the HP region</td><td>CNS tumours near or within the HP region</td></tr><tr><td style=\"white-space:nowrap\">16.1<a name=\"cs-riskfactor-eu-pcsp-16.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region< 30 Gy</td><td>Radiotherapy to a vol exposing the HP region< 30 Gy</td></tr><tr><td style=\"white-space:nowrap\">16.2<a name=\"cs-riskfactor-eu-pcsp-16.462\"> </a></td><td>Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)</td><td>Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)</td></tr><tr><td style=\"white-space:nowrap\">17.1<a name=\"cs-riskfactor-eu-pcsp-17.461\"> </a></td><td>Radiotherapy to a vol exposing the HP region</td><td>Radiotherapy to a vol exposing the HP region</td></tr><tr><td style=\"white-space:nowrap\">17.5<a name=\"cs-riskfactor-eu-pcsp-17.465\"> </a></td><td>hydrocephalus or cerebrospinal fluid shunt</td><td>hydrocephalus or cerebrospinal fluid shunt</td></tr><tr><td style=\"white-space:nowrap\">19.3<a name=\"cs-riskfactor-eu-pcsp-19.463\"> </a></td><td>Radioiodine therapy (I-131 ablation therapy)</td><td>Radioiodine therapy (I-131 ablation therapy)</td></tr><tr><td style=\"white-space:nowrap\">19.5<a name=\"cs-riskfactor-eu-pcsp-19.465\"> </a></td><td>Allogenic HSCT</td><td>Allogenic HSCT</td></tr><tr><td style=\"white-space:nowrap\">19.6<a name=\"cs-riskfactor-eu-pcsp-19.466\"> </a></td><td>Total thyroidectomy</td><td>Total thyroidectomy</td></tr><tr><td style=\"white-space:nowrap\">20.1<a name=\"cs-riskfactor-eu-pcsp-20.461\"> </a></td><td>RT to a vol exposing the head, brain or neck</td><td>RT to a vol exposing the head, brain or neck</td></tr><tr><td style=\"white-space:nowrap\">21.1<a name=\"cs-riskfactor-eu-pcsp-21.461\"> </a></td><td>History of a central nervous system tumor</td><td>History of a central nervous system tumor</td></tr><tr><td style=\"white-space:nowrap\">21.2<a name=\"cs-riskfactor-eu-pcsp-21.462\"> </a></td><td>RT to a vol exposing the brain ANY DOSE</td><td>RT to a vol exposing the brain ANY DOSE</td></tr><tr><td style=\"white-space:nowrap\">21.4<a name=\"cs-riskfactor-eu-pcsp-21.464\"> </a></td><td>Brain surgery</td><td>Brain surgery</td></tr><tr><td style=\"white-space:nowrap\">21.5<a name=\"cs-riskfactor-eu-pcsp-21.465\"> </a></td><td>High dose cytarabine IV (intravenous)</td><td>High dose cytarabine IV (intravenous)</td></tr><tr><td style=\"white-space:nowrap\">21.6<a name=\"cs-riskfactor-eu-pcsp-21.466\"> </a></td><td>High dose MTX IV</td><td>High dose MTX IV</td></tr><tr><td style=\"white-space:nowrap\">21.7<a name=\"cs-riskfactor-eu-pcsp-21.467\"> </a></td><td>Any Chemotherapy IT (intrathecal)</td><td>Any Chemotherapy IT (intrathecal)</td></tr><tr><td style=\"white-space:nowrap\">22.1<a name=\"cs-riskfactor-eu-pcsp-22.461\"> </a></td><td>Vinca-Alkaloids</td><td>Vinca-Alkaloids</td></tr><tr><td style=\"white-space:nowrap\">22.2<a name=\"cs-riskfactor-eu-pcsp-22.462\"> </a></td><td>Cisplatin or carboplatin</td><td>Cisplatin or carboplatin</td></tr><tr><td style=\"white-space:nowrap\">23.1<a name=\"cs-riskfactor-eu-pcsp-23.461\"> </a></td><td>RT to a vol exposing the lens</td><td>RT to a vol exposing the lens</td></tr><tr><td style=\"white-space:nowrap\">24.1<a name=\"cs-riskfactor-eu-pcsp-24.461\"> </a></td><td>RT to a vol exposing the eye and orbit</td><td>RT to a vol exposing the eye and orbit</td></tr><tr><td style=\"white-space:nowrap\">25.1<a name=\"cs-riskfactor-eu-pcsp-25.461\"> </a></td><td>RT to a vol exposing the craniofacial area, especially after high doses and at a young age</td><td>RT to a vol exposing the craniofacial area, especially after high doses and at a young age</td></tr><tr><td style=\"white-space:nowrap\">25.3<a name=\"cs-riskfactor-eu-pcsp-25.463\"> </a></td><td>Surgery to the face, especially at a young age</td><td>Surgery to the face, especially at a young age</td></tr><tr><td style=\"white-space:nowrap\">26.1<a name=\"cs-riskfactor-eu-pcsp-26.461\"> </a></td><td>Surgery of the spine</td><td>Surgery of the spine</td></tr><tr><td style=\"white-space:nowrap\">26.2<a name=\"cs-riskfactor-eu-pcsp-26.462\"> </a></td><td>Surgery of the chest (Does not include CVC pose)</td><td>Surgery of the chest (Does not include CVC pose)</td></tr><tr><td style=\"white-space:nowrap\">26.3<a name=\"cs-riskfactor-eu-pcsp-26.463\"> </a></td><td>RT to a vol exposing the spine</td><td>RT to a vol exposing the spine</td></tr><tr><td style=\"white-space:nowrap\">26.4<a name=\"cs-riskfactor-eu-pcsp-26.464\"> </a></td><td>Spinal or paraspinal malignancies</td><td>Spinal or paraspinal malignancies</td></tr><tr><td style=\"white-space:nowrap\">27.1<a name=\"cs-riskfactor-eu-pcsp-27.461\"> </a></td><td>Cyclophosphamide</td><td>Cyclophosphamide</td></tr><tr><td style=\"white-space:nowrap\">27.3<a name=\"cs-riskfactor-eu-pcsp-27.463\"> </a></td><td>RT to a vol exposing the bladder</td><td>RT to a vol exposing the bladder</td></tr><tr><td style=\"white-space:nowrap\">27.5<a name=\"cs-riskfactor-eu-pcsp-27.465\"> </a></td><td>Cystectomy</td><td>Cystectomy</td></tr><tr><td style=\"white-space:nowrap\">27.6<a name=\"cs-riskfactor-eu-pcsp-27.466\"> </a></td><td>Hysterectomy</td><td>Hysterectomy</td></tr><tr><td style=\"white-space:nowrap\">27.7<a name=\"cs-riskfactor-eu-pcsp-27.467\"> </a></td><td>Pelvic surgery</td><td>Pelvic surgery</td></tr><tr><td style=\"white-space:nowrap\">27.8<a name=\"cs-riskfactor-eu-pcsp-27.468\"> </a></td><td>Spinal cord surgery</td><td>Spinal cord surgery</td></tr><tr><td style=\"white-space:nowrap\">28.1<a name=\"cs-riskfactor-eu-pcsp-28.461\"> </a></td><td>RT to a vol exposing the uterus only female</td><td>RT to a vol exposing the uterus only female</td></tr><tr><td style=\"white-space:nowrap\">29.1<a name=\"cs-riskfactor-eu-pcsp-29.461\"> </a></td><td>RT to a vol exposing the oral cavity or salivary glands</td><td>RT to a vol exposing the oral cavity or salivary glands</td></tr><tr><td style=\"white-space:nowrap\">29.4<a name=\"cs-riskfactor-eu-pcsp-29.464\"> </a></td><td>Chemotherapy</td><td>Chemotherapy</td></tr><tr><td style=\"white-space:nowrap\">30.1<a name=\"cs-riskfactor-eu-pcsp-30.461\"> </a></td><td>RT to a vol exposing the gastro-intestinal tract</td><td>RT to a vol exposing the gastro-intestinal tract</td></tr><tr><td style=\"white-space:nowrap\">30.3<a name=\"cs-riskfactor-eu-pcsp-30.463\"> </a></td><td>Oesophageal surgery</td><td>Oesophageal surgery</td></tr><tr><td style=\"white-space:nowrap\">30.4<a name=\"cs-riskfactor-eu-pcsp-30.464\"> </a></td><td>Abdominal surgery</td><td>Abdominal surgery</td></tr><tr><td style=\"white-space:nowrap\">30.5<a name=\"cs-riskfactor-eu-pcsp-30.465\"> </a></td><td>With a history of chronic GVHD</td><td>With a history of chronic GVHD</td></tr><tr><td style=\"white-space:nowrap\">31.1<a name=\"cs-riskfactor-eu-pcsp-31.461\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">32.1<a name=\"cs-riskfactor-eu-pcsp-32.461\"> </a></td><td>RT to a vol exposing the lungs</td><td>RT to a vol exposing the lungs</td></tr><tr><td style=\"white-space:nowrap\">32.3<a name=\"cs-riskfactor-eu-pcsp-32.463\"> </a></td><td>Bleomycin</td><td>Bleomycin</td></tr><tr><td style=\"white-space:nowrap\">32.4<a name=\"cs-riskfactor-eu-pcsp-32.464\"> </a></td><td>Busulfan</td><td>Busulfan</td></tr><tr><td style=\"white-space:nowrap\">32.5<a name=\"cs-riskfactor-eu-pcsp-32.465\"> </a></td><td>BCNU Carmustine</td><td>BCNU Carmustine</td></tr><tr><td style=\"white-space:nowrap\">32.6<a name=\"cs-riskfactor-eu-pcsp-32.466\"> </a></td><td>CCNU Lomustine</td><td>CCNU Lomustine</td></tr><tr><td style=\"white-space:nowrap\">32.7<a name=\"cs-riskfactor-eu-pcsp-32.467\"> </a></td><td>Thoracic surgery</td><td>Thoracic surgery</td></tr><tr><td style=\"white-space:nowrap\">33.1<a name=\"cs-riskfactor-eu-pcsp-33.461\"> </a></td><td>Cisplatin Any dose</td><td>Cisplatin Any dose</td></tr><tr><td style=\"white-space:nowrap\">33.2<a name=\"cs-riskfactor-eu-pcsp-33.462\"> </a></td><td>Ifosfamide Any dose</td><td>Ifosfamide Any dose</td></tr><tr><td style=\"white-space:nowrap\">33.3<a name=\"cs-riskfactor-eu-pcsp-33.463\"> </a></td><td>Carboplatin Any dose</td><td>Carboplatin Any dose</td></tr><tr><td style=\"white-space:nowrap\">34.1<a name=\"cs-riskfactor-eu-pcsp-34.461\"> </a></td><td>RT to a volume exposing the liver</td><td>RT to a volume exposing the liver</td></tr><tr><td style=\"white-space:nowrap\">34.10<a name=\"cs-riskfactor-eu-pcsp-34.4610\"> </a></td><td>Chronic GVHD</td><td>Chronic GVHD</td></tr><tr><td style=\"white-space:nowrap\">34.11<a name=\"cs-riskfactor-eu-pcsp-34.4611\"> </a></td><td>Liver surgery</td><td>Liver surgery</td></tr><tr><td style=\"white-space:nowrap\">34.3<a name=\"cs-riskfactor-eu-pcsp-34.463\"> </a></td><td>HSCT (irrespective of GVHD)</td><td>HSCT (irrespective of GVHD)</td></tr><tr><td style=\"white-space:nowrap\">34.5<a name=\"cs-riskfactor-eu-pcsp-34.465\"> </a></td><td>Mercaptopurine Thioguanine</td><td>Mercaptopurine Thioguanine</td></tr><tr><td style=\"white-space:nowrap\">34.6<a name=\"cs-riskfactor-eu-pcsp-34.466\"> </a></td><td>Dactinomycin</td><td>Dactinomycin</td></tr><tr><td style=\"white-space:nowrap\">34.8<a name=\"cs-riskfactor-eu-pcsp-34.468\"> </a></td><td>Chronic viral hepatitis</td><td>Chronic viral hepatitis</td></tr><tr><td style=\"white-space:nowrap\">34.9<a name=\"cs-riskfactor-eu-pcsp-34.469\"> </a></td><td>Sinusoidal obstruction syndrome</td><td>Sinusoidal obstruction syndrome</td></tr><tr><td style=\"white-space:nowrap\">35.1<a name=\"cs-riskfactor-eu-pcsp-35.461\"> </a></td><td>HSCT (irrespective of GVHD)</td><td>HSCT (irrespective of GVHD)</td></tr><tr><td style=\"white-space:nowrap\">35.2<a name=\"cs-riskfactor-eu-pcsp-35.462\"> </a></td><td>Multiple red blood cell transfusions</td><td>Multiple red blood cell transfusions</td></tr><tr><td style=\"white-space:nowrap\">36.1<a name=\"cs-riskfactor-eu-pcsp-36.461\"> </a></td><td>Splenectomy</td><td>Splenectomy</td></tr><tr><td style=\"white-space:nowrap\">36.2<a name=\"cs-riskfactor-eu-pcsp-36.462\"> </a></td><td>RT >= 10 Gy to a vol exposing the spleen</td><td>RT >= 10 Gy to a vol exposing the spleen</td></tr><tr><td style=\"white-space:nowrap\">36.3<a name=\"cs-riskfactor-eu-pcsp-36.463\"> </a></td><td>Allogenic HSCT (with or without TBI)</td><td>Allogenic HSCT (with or without TBI)</td></tr><tr><td style=\"white-space:nowrap\">36.4<a name=\"cs-riskfactor-eu-pcsp-36.464\"> </a></td><td>Autologus HSCT conditioned with TBI</td><td>Autologus HSCT conditioned with TBI</td></tr><tr><td style=\"white-space:nowrap\">37.1<a name=\"cs-riskfactor-eu-pcsp-37.461\"> </a></td><td>Hereditary cancer sd</td><td>Hereditary cancer sd</td></tr><tr><td style=\"white-space:nowrap\">38.1<a name=\"cs-riskfactor-eu-pcsp-38.461\"> </a></td><td>Any RT including TBI (predominantly in the RT field)</td><td>Any RT including TBI (predominantly in the RT field)</td></tr><tr><td style=\"white-space:nowrap\">38.2<a name=\"cs-riskfactor-eu-pcsp-38.462\"> </a></td><td>HSCT Especially with a history of skin GvHD</td><td>HSCT Especially with a history of skin GvHD</td></tr><tr><td style=\"white-space:nowrap\">39.1<a name=\"cs-riskfactor-eu-pcsp-39.461\"> </a></td><td>RT to a vol exposing the colon and rectum</td><td>RT to a vol exposing the colon and rectum</td></tr><tr><td style=\"white-space:nowrap\">40.1<a name=\"cs-riskfactor-eu-pcsp-40.461\"> </a></td><td>RT to a vol exposing the oral cavity</td><td>RT to a vol exposing the oral cavity</td></tr><tr><td style=\"white-space:nowrap\">41.2<a name=\"cs-riskfactor-eu-pcsp-41.462\"> </a></td><td>Anthracyclines and/or Mitoxantrone</td><td>Anthracyclines and/or Mitoxantrone</td></tr><tr><td style=\"white-space:nowrap\">41.3<a name=\"cs-riskfactor-eu-pcsp-41.463\"> </a></td><td>Epipodophyllotoxins or autologous</td><td>Epipodophyllotoxins or autologous</td></tr><tr><td style=\"white-space:nowrap\">41.4<a name=\"cs-riskfactor-eu-pcsp-41.464\"> </a></td><td>Autologous haematopoietic stem cell transplant</td><td>Autologous haematopoietic stem cell transplant</td></tr><tr><td style=\"white-space:nowrap\">42.1<a name=\"cs-riskfactor-eu-pcsp-42.461\"> </a></td><td>Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)</td><td>Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)</td></tr><tr><td style=\"white-space:nowrap\">45.1<a name=\"cs-riskfactor-eu-pcsp-45.461\"> </a></td><td>RT to a vol exposing the head or brain</td><td>RT to a vol exposing the head or brain</td></tr><tr><td style=\"white-space:nowrap\">46.1<a name=\"cs-riskfactor-eu-pcsp-46.461\"> </a></td><td>RT between 15 and 35 Gy to a vol exposing the heart</td><td>RT between 15 and 35 Gy to a vol exposing the heart</td></tr><tr><td style=\"white-space:nowrap\">46.2<a name=\"cs-riskfactor-eu-pcsp-46.462\"> </a></td><td>Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2</td><td>Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2</td></tr><tr><td style=\"white-space:nowrap\">47.1<a name=\"cs-riskfactor-eu-pcsp-47.461\"> </a></td><td>RT to a vol exposing the kidney or urinary tract</td><td>RT to a vol exposing the kidney or urinary tract</td></tr></table></div>"
},
"url" : "http://hl7.eu/fhir/ig/pcsp/CodeSystem/cs-riskfactor-eu-pcsp",
"version" : "0.2.0",
"name" : "CsRiskFactorPcsp",
"title" : "Risk Factors",
"status" : "draft",
"experimental" : false,
"date" : "2024-09-11T13:25:13+00:00",
"publisher" : "PanCareSurPass Project",
"contact" : [
{
"name" : "PanCareSurPass Project",
"telecom" : [
{
"system" : "url",
"value" : "https://www.pancaresurpass.eu/"
}
]
},
{
"name" : "PanCareSurPass Project",
"telecom" : [
{
"system" : "url",
"value" : "https://www.pancaresurpass.eu/"
}
]
}
],
"description" : "Risk Factors used by the PCSP algorithm",
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "150",
"display" : "Europe"
}
]
}
],
"caseSensitive" : true,
"content" : "complete",
"count" : 112,
"concept" : [
{
"code" : "1.1",
"display" : "RT to a vol exposing the thyroid gland",
"definition" : "RT to a vol exposing the thyroid gland"
},
{
"code" : "1.2",
"display" : "TBI",
"definition" : "TBI"
},
{
"code" : "1.3",
"display" : "MIBG therapy (I-131 MIBG therapy)",
"definition" : "MIBG therapy (I-131 MIBG therapy)"
},
{
"code" : "2.1",
"display" : "RT >= 10 Gy to a vol exposing the breasts",
"definition" : "RT >= 10 Gy to a vol exposing the breasts"
},
{
"code" : "2.2",
"display" : "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age",
"definition" : "OR upper abdominal field radiation that can extend above the diaphragm likely exposing breast tissue at a young age"
},
{
"code" : "3.1",
"display" : "RT >= 35 Gy to a vol exposing the heart",
"definition" : "RT >= 35 Gy to a vol exposing the heart"
},
{
"code" : "3.2",
"display" : "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2",
"definition" : "Anthracyclines (doxorubicin isotoxic equivalents)>= 250 mg/m2"
},
{
"code" : "3.3",
"display" : "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2",
"definition" : "RT >= 15 Gy to a vol exposing the heart AND Anthracyclines (doxorubicin isotoxic equivalents)>= 100 mg/m2"
},
{
"code" : "4.1",
"display" : "Alkylating agents",
"definition" : "Alkylating agents"
},
{
"code" : "4.2",
"display" : "RT to a vol exposing the testes",
"definition" : "RT to a vol exposing the testes"
},
{
"code" : "4.3",
"display" : "Including TBI",
"definition" : "Including TBI"
},
{
"code" : "5.1",
"display" : "RT >=12 Gy to a vol exposing the testicles",
"definition" : "RT >=12 Gy to a vol exposing the testicles"
},
{
"code" : "6.3",
"display" : "Surgery to the spinal cord, sympathetic nerves or pelvis",
"definition" : "Surgery to the spinal cord, sympathetic nerves or pelvis"
},
{
"code" : "6.4",
"display" : "Hypogonadal",
"definition" : "Hypogonadal"
},
{
"code" : "7.2",
"display" : "RT to a vol exposing the ovaries",
"definition" : "RT to a vol exposing the ovaries"
},
{
"code" : "8.1",
"display" : "RT >= 30 Gy to a vol exposing the head or the brain",
"definition" : "RT >= 30 Gy to a vol exposing the head or the brain"
},
{
"code" : "8.2",
"display" : "Cisplatin (with or without carboplatin > 1500 mg/m2)",
"definition" : "Cisplatin (with or without carboplatin > 1500 mg/m2)"
},
{
"code" : "9.1",
"display" : "RT to a vol exposing the pancreas",
"definition" : "RT to a vol exposing the pancreas"
},
{
"code" : "10.2",
"display" : "HSCT",
"definition" : "HSCT"
},
{
"code" : "11.1",
"display" : "RT to a volume exposing the hypothalamus or pituatary gland",
"definition" : "RT to a volume exposing the hypothalamus or pituatary gland"
},
{
"code" : "11.3",
"display" : "Hypothalamic or pituitary tumour",
"definition" : "Hypothalamic or pituitary tumour"
},
{
"code" : "11.4",
"display" : "Neurosurgery of the hypothalamus or pituitary gland",
"definition" : "Neurosurgery of the hypothalamus or pituitary gland"
},
{
"code" : "12.1",
"display" : "RT to a vol exposing the kidneys, heart and associated large vessels",
"definition" : "RT to a vol exposing the kidneys, heart and associated large vessels"
},
{
"code" : "12.3",
"display" : "Nephrectomy",
"definition" : "Nephrectomy"
},
{
"code" : "12.4",
"display" : "Ifosfamide",
"definition" : "Ifosfamide"
},
{
"code" : "12.5",
"display" : "Platinium based chemotherapy",
"definition" : "Platinium based chemotherapy"
},
{
"code" : "12.6",
"display" : "Nitrosureas",
"definition" : "Nitrosureas"
},
{
"code" : "12.7",
"display" : "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)",
"definition" : "Immunosuppressives treatment and prolonged steroids as anticancer treatment (at least 4 weeks, continuously)"
},
{
"code" : "13.1",
"display" : "Cranial and/or spinal RT",
"definition" : "Cranial and/or spinal RT"
},
{
"code" : "13.3",
"display" : "Methotrexate",
"definition" : "Methotrexate"
},
{
"code" : "13.4",
"display" : "Gonadal failure",
"definition" : "Gonadal failure"
},
{
"code" : "13.5",
"display" : "Growth hormone deficiency",
"definition" : "Growth hormone deficiency"
},
{
"code" : "13.6",
"display" : "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment",
"definition" : "Prolonged (at least 4 weeks, continuously) corticosteroids as anti-cancer treatment"
},
{
"code" : "13.7",
"display" : "HSCT, especially with an history of GVHD",
"definition" : "HSCT, especially with an history of GVHD"
},
{
"code" : "14.3",
"display" : "High dose RT",
"definition" : "High dose RT"
},
{
"code" : "15.1",
"display" : "Radiotherapy to a vol exposing the HP region >= 30 Gy",
"definition" : "Radiotherapy to a vol exposing the HP region >= 30 Gy"
},
{
"code" : "15.2",
"display" : "Surgery near or within the HP region",
"definition" : "Surgery near or within the HP region"
},
{
"code" : "15.3",
"display" : "CNS tumours near or within the HP region",
"definition" : "CNS tumours near or within the HP region"
},
{
"code" : "16.1",
"display" : "Radiotherapy to a vol exposing the HP region< 30 Gy",
"definition" : "Radiotherapy to a vol exposing the HP region< 30 Gy"
},
{
"code" : "16.2",
"display" : "Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)",
"definition" : "Hydrocephalus or cerebrospinal fluid shunt(Risk factor for GHD)"
},
{
"code" : "17.1",
"display" : "Radiotherapy to a vol exposing the HP region",
"definition" : "Radiotherapy to a vol exposing the HP region"
},
{
"code" : "17.5",
"display" : "hydrocephalus or cerebrospinal fluid shunt",
"definition" : "hydrocephalus or cerebrospinal fluid shunt"
},
{
"code" : "19.3",
"display" : "Radioiodine therapy (I-131 ablation therapy)",
"definition" : "Radioiodine therapy (I-131 ablation therapy)"
},
{
"code" : "19.5",
"display" : "Allogenic HSCT",
"definition" : "Allogenic HSCT"
},
{
"code" : "19.6",
"display" : "Total thyroidectomy",
"definition" : "Total thyroidectomy"
},
{
"code" : "20.1",
"display" : "RT to a vol exposing the head, brain or neck",
"definition" : "RT to a vol exposing the head, brain or neck"
},
{
"code" : "21.1",
"display" : "History of a central nervous system tumor",
"definition" : "History of a central nervous system tumor"
},
{
"code" : "21.2",
"display" : "RT to a vol exposing the brain ANY DOSE",
"definition" : "RT to a vol exposing the brain ANY DOSE"
},
{
"code" : "21.4",
"display" : "Brain surgery",
"definition" : "Brain surgery"
},
{
"code" : "21.5",
"display" : "High dose cytarabine IV (intravenous)",
"definition" : "High dose cytarabine IV (intravenous)"
},
{
"code" : "21.6",
"display" : "High dose MTX IV",
"definition" : "High dose MTX IV"
},
{
"code" : "21.7",
"display" : "Any Chemotherapy IT (intrathecal)",
"definition" : "Any Chemotherapy IT (intrathecal)"
},
{
"code" : "22.1",
"display" : "Vinca-Alkaloids",
"definition" : "Vinca-Alkaloids"
},
{
"code" : "22.2",
"display" : "Cisplatin or carboplatin",
"definition" : "Cisplatin or carboplatin"
},
{
"code" : "23.1",
"display" : "RT to a vol exposing the lens",
"definition" : "RT to a vol exposing the lens"
},
{
"code" : "24.1",
"display" : "RT to a vol exposing the eye and orbit",
"definition" : "RT to a vol exposing the eye and orbit"
},
{
"code" : "25.1",
"display" : "RT to a vol exposing the craniofacial area, especially after high doses and at a young age",
"definition" : "RT to a vol exposing the craniofacial area, especially after high doses and at a young age"
},
{
"code" : "25.3",
"display" : "Surgery to the face, especially at a young age",
"definition" : "Surgery to the face, especially at a young age"
},
{
"code" : "26.1",
"display" : "Surgery of the spine",
"definition" : "Surgery of the spine"
},
{
"code" : "26.2",
"display" : "Surgery of the chest (Does not include CVC pose)",
"definition" : "Surgery of the chest (Does not include CVC pose)"
},
{
"code" : "26.3",
"display" : "RT to a vol exposing the spine",
"definition" : "RT to a vol exposing the spine"
},
{
"code" : "26.4",
"display" : "Spinal or paraspinal malignancies",
"definition" : "Spinal or paraspinal malignancies"
},
{
"code" : "27.1",
"display" : "Cyclophosphamide",
"definition" : "Cyclophosphamide"
},
{
"code" : "27.3",
"display" : "RT to a vol exposing the bladder",
"definition" : "RT to a vol exposing the bladder"
},
{
"code" : "27.5",
"display" : "Cystectomy",
"definition" : "Cystectomy"
},
{
"code" : "27.6",
"display" : "Hysterectomy",
"definition" : "Hysterectomy"
},
{
"code" : "27.7",
"display" : "Pelvic surgery",
"definition" : "Pelvic surgery"
},
{
"code" : "27.8",
"display" : "Spinal cord surgery",
"definition" : "Spinal cord surgery"
},
{
"code" : "28.1",
"display" : "RT to a vol exposing the uterus only female",
"definition" : "RT to a vol exposing the uterus only female"
},
{
"code" : "29.1",
"display" : "RT to a vol exposing the oral cavity or salivary glands",
"definition" : "RT to a vol exposing the oral cavity or salivary glands"
},
{
"code" : "29.4",
"display" : "Chemotherapy",
"definition" : "Chemotherapy"
},
{
"code" : "30.1",
"display" : "RT to a vol exposing the gastro-intestinal tract",
"definition" : "RT to a vol exposing the gastro-intestinal tract"
},
{
"code" : "30.3",
"display" : "Oesophageal surgery",
"definition" : "Oesophageal surgery"
},
{
"code" : "30.4",
"display" : "Abdominal surgery",
"definition" : "Abdominal surgery"
},
{
"code" : "30.5",
"display" : "With a history of chronic GVHD",
"definition" : "With a history of chronic GVHD"
},
{
"code" : "31.1",
"display" : "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2",
"definition" : "Anthracyclines (doxorubicin isotoxic equivalents) <100 mg/m2"
},
{
"code" : "32.1",
"display" : "RT to a vol exposing the lungs",
"definition" : "RT to a vol exposing the lungs"
},
{
"code" : "32.3",
"display" : "Bleomycin",
"definition" : "Bleomycin"
},
{
"code" : "32.4",
"display" : "Busulfan",
"definition" : "Busulfan"
},
{
"code" : "32.5",
"display" : "BCNU Carmustine",
"definition" : "BCNU Carmustine"
},
{
"code" : "32.6",
"display" : "CCNU Lomustine",
"definition" : "CCNU Lomustine"
},
{
"code" : "32.7",
"display" : "Thoracic surgery",
"definition" : "Thoracic surgery"
},
{
"code" : "33.1",
"display" : "Cisplatin Any dose",
"definition" : "Cisplatin Any dose"
},
{
"code" : "33.2",
"display" : "Ifosfamide Any dose",
"definition" : "Ifosfamide Any dose"
},
{
"code" : "33.3",
"display" : "Carboplatin Any dose",
"definition" : "Carboplatin Any dose"
},
{
"code" : "34.1",
"display" : "RT to a volume exposing the liver",
"definition" : "RT to a volume exposing the liver"
},
{
"code" : "34.10",
"display" : "Chronic GVHD",
"definition" : "Chronic GVHD"
},
{
"code" : "34.11",
"display" : "Liver surgery",
"definition" : "Liver surgery"
},
{
"code" : "34.3",
"display" : "HSCT (irrespective of GVHD)",
"definition" : "HSCT (irrespective of GVHD)"
},
{
"code" : "34.5",
"display" : "Mercaptopurine Thioguanine",
"definition" : "Mercaptopurine Thioguanine"
},
{
"code" : "34.6",
"display" : "Dactinomycin",
"definition" : "Dactinomycin"
},
{
"code" : "34.8",
"display" : "Chronic viral hepatitis",
"definition" : "Chronic viral hepatitis"
},
{
"code" : "34.9",
"display" : "Sinusoidal obstruction syndrome",
"definition" : "Sinusoidal obstruction syndrome"
},
{
"code" : "35.1",
"display" : "HSCT (irrespective of GVHD)",
"definition" : "HSCT (irrespective of GVHD)"
},
{
"code" : "35.2",
"display" : "Multiple red blood cell transfusions",
"definition" : "Multiple red blood cell transfusions"
},
{
"code" : "36.1",
"display" : "Splenectomy",
"definition" : "Splenectomy"
},
{
"code" : "36.2",
"display" : "RT >= 10 Gy to a vol exposing the spleen",
"definition" : "RT >= 10 Gy to a vol exposing the spleen"
},
{
"code" : "36.3",
"display" : "Allogenic HSCT (with or without TBI)",
"definition" : "Allogenic HSCT (with or without TBI)"
},
{
"code" : "36.4",
"display" : "Autologus HSCT conditioned with TBI",
"definition" : "Autologus HSCT conditioned with TBI"
},
{
"code" : "37.1",
"display" : "Hereditary cancer sd",
"definition" : "Hereditary cancer sd"
},
{
"code" : "38.1",
"display" : "Any RT including TBI (predominantly in the RT field)",
"definition" : "Any RT including TBI (predominantly in the RT field)"
},
{
"code" : "38.2",
"display" : "HSCT Especially with a history of skin GvHD",
"definition" : "HSCT Especially with a history of skin GvHD"
},
{
"code" : "39.1",
"display" : "RT to a vol exposing the colon and rectum",
"definition" : "RT to a vol exposing the colon and rectum"
},
{
"code" : "40.1",
"display" : "RT to a vol exposing the oral cavity",
"definition" : "RT to a vol exposing the oral cavity"
},
{
"code" : "41.2",
"display" : "Anthracyclines and/or Mitoxantrone",
"definition" : "Anthracyclines and/or Mitoxantrone"
},
{
"code" : "41.3",
"display" : "Epipodophyllotoxins or autologous",
"definition" : "Epipodophyllotoxins or autologous"
},
{
"code" : "41.4",
"display" : "Autologous haematopoietic stem cell transplant",
"definition" : "Autologous haematopoietic stem cell transplant"
},
{
"code" : "42.1",
"display" : "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)",
"definition" : "Ciclofosfamide, Ifosfamide (particularly if they have a history of severe hemorrhagic cystitis)"
},
{
"code" : "45.1",
"display" : "RT to a vol exposing the head or brain",
"definition" : "RT to a vol exposing the head or brain"
},
{
"code" : "46.1",
"display" : "RT between 15 and 35 Gy to a vol exposing the heart",
"definition" : "RT between 15 and 35 Gy to a vol exposing the heart"
},
{
"code" : "46.2",
"display" : "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2",
"definition" : "Anthracyclines (doxorubicin isotoxic equivalents) between 100 and 250 mg/m2"
},
{
"code" : "47.1",
"display" : "RT to a vol exposing the kidney or urinary tract",
"definition" : "RT to a vol exposing the kidney or urinary tract"
}
]
}
IG © 2021+ PanCareSurPass Project. Package hl7.eu.fhir.pcsp#0.2.0 based on FHIR 4.0.1. Generated 2024-09-11
Links: Table of Contents |
QA Report
The PanCareSurPass Research and Innovation Action has received funding from the European Union's Horizon 2020
research and innovation programme under grant agreement No. 899999.
